7 unchanged sentences
Specimen Common Stock Certificate
+Added: Consulting Agreement effective as of October 1, 2022, by and between CytomX Therapeutics, Inc.
+Added: and Carlos Campoy .
+Added: Consulting Agreement effective as of September 13, 2022, by and between CytomX Therapeutics, Inc.
+Added: Peterson, M.D.
+Added: Separation Agreement effective as of September 30, 2022, by and between CytomX Therapeutics, Inc.
+Added: and Carlos Campoy.
+Added: Separation Agreement effective as of September 12, 2022, by and between CytomX Therapeutics, Inc.
+Added: Peterson, M.D.
+Added: Separation Agreement effective as of September 30, 2022, by and between CytomX Therapeutics, Inc.
+Added: and Alison Hannah, M.D.
+Added: Amendment No 3 to Collaboration and License Agreement, dated May 23, 2014, by and between the Company and Bristol Myers Squibb Company, effective as of October 11, 2022.
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).
−Removed: Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).
+Added: Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).
Certification of Chief Executive Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.
−Removed: Certification of Chief Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.
+Added: Certification of Principal Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
5 unchanged sentences
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
+Added: Certain confidential portions of this exhibit have been omitted from this exhibit.
+Added: # Indicates management contract or compensatory plan.
* The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of CytomX Therapeutics, Inc.
2 unchanged sentences
CytomX Therapeutics, Inc.
−Removed: August 4, 2022
+Added: November 8, 2022
Chief Executive Officer and Chairman
(Principal Executive Officer)
−Removed: August 4, 2022
−Removed: /s/ Carlos Campoy
−Removed: Carlos Campoy
−Removed: Chief Financial Officer
+Added: November 8, 2022
+Added: /s/ Christopher W.
+Added: Christopher W.
+Added: Senior Vice President, Finance and Accounting
(Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.